TY - JOUR
T1 - Superior vena cava syndrome
AU - Pearl, Michael L.
AU - Buhl, Ann
AU - DiSilvestro, Paul A.
AU - Valea, Fidel A.
AU - Chalas, Eva
PY - 2002
Y1 - 2002
N2 - Superior vena cava syndrome (SVCS) affects approximately 15,000 people annually in the United States. Currently, mediastinal malignancies, primarily small cell lung cancer, account for the majority of cases of SVCS. Iatrogenic causes, predominantly long-term central venous catheters, account for approximately 7% of cases of SVCS, and the incidence is increasing. Historically, SVCS was considered an oncologic emergency that required urgent treatment. It is now evident that SVCS is rarely a true emergency and that treatment may be safely provided in a deliberate fashion to the majority of patients. This article provides an overview of the etiology, presentation, diagnosis, and management of SVCS.
AB - Superior vena cava syndrome (SVCS) affects approximately 15,000 people annually in the United States. Currently, mediastinal malignancies, primarily small cell lung cancer, account for the majority of cases of SVCS. Iatrogenic causes, predominantly long-term central venous catheters, account for approximately 7% of cases of SVCS, and the incidence is increasing. Historically, SVCS was considered an oncologic emergency that required urgent treatment. It is now evident that SVCS is rarely a true emergency and that treatment may be safely provided in a deliberate fashion to the majority of patients. This article provides an overview of the etiology, presentation, diagnosis, and management of SVCS.
UR - http://www.scopus.com/inward/record.url?scp=0036756175&partnerID=8YFLogxK
U2 - 10.1016/S1068-607X(02)00109-9
DO - 10.1016/S1068-607X(02)00109-9
M3 - Article
AN - SCOPUS:0036756175
SN - 1068-607X
VL - 9
SP - 160
EP - 163
JO - Primary Care Update for Ob/Gyns
JF - Primary Care Update for Ob/Gyns
IS - 5
ER -